8-K: Akebia's Vafseo Receives FDA Approval for Anemia Treatment in Dialysis Patients

Akebia Therapeutics has secured FDA approval for Vafseo (vadadustat) tablets, a new oral treatment for anemia in adult patients on dialysis due to chronic kidney disease.

Summary

• Akebia Therapeutics announced that the FDA has approved Vafseo (vadadustat) tablets for treating anemia caused by chronic kidney disease in adults who have been on dialysis for at least three months.
• Vafseo is a once-daily oral medication that works by stimulating the body's natural production of erythropoietin, a hormone that helps produce red blood cells.
• The approval is based on data from the INNO2VATE program and post-marketing safety data from Japan, where Vafseo was launched in August 2020.
• Approximately 500,000 adult patients in the U.S. on dialysis suffer from anemia due to chronic kidney disease.
• Akebia plans to commercialize Vafseo in the U.S. with its existing commercial team and through its relationship with CSL Vifor.

Sentiment

Score: 7

Explanation: The document is positive due to the FDA approval of Vafseo, but the boxed warning and potential risks temper the overall sentiment. The company's plans for commercialization and the potential for a new standard of care are encouraging.

Positives

• Vafseo offers a new oral treatment option for anemia in dialysis patients, potentially improving patient convenience.
• The drug is approved in 37 countries, indicating a global market opportunity.
• Akebia has an established commercial team and a partnership with CSL Vifor to support the launch.
• The approval is based on robust clinical trial data and post-marketing safety data.

Negatives

• Vafseo carries a boxed warning regarding increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.
• The drug is not recommended for patients with active malignancies or those with cirrhosis or active, acute liver disease.
• There are potential drug interactions with iron supplements, iron-containing phosphate binders, non-iron-containing phosphate binders, BCRP substrates, and statins.
• The safety of Vafseo has not been established for the treatment of anemia due to CKD in adults not on dialysis.

Risks

• There is a risk of thrombotic vascular events, including major adverse cardiovascular events (MACE), associated with Vafseo.
• Hepatocellular injury has been reported in less than 1% of patients, requiring monitoring of liver function.
• Worsening of hypertension and seizures have been reported in patients receiving Vafseo.
• Gastrointestinal erosions, including GI bleeding, have been reported.
• The commercial success of Vafseo depends on market acceptance, coverage, and reimbursement.

Future Outlook

Akebia plans to execute a launch strategy to drive Vafseo toward becoming a new oral standard of care for adult dialysis patients, with commercial availability expected in the near future.

Management Comments

• John P. Butler, Chief Executive Officer of Akebia, stated that they are proud to deliver an alternative treatment option for the hundreds of thousands of Americans on dialysis who are diagnosed with anemia due to CKD.
• Mr. Butler added that this milestone is the culmination of years of perseverance by Akebia employees and partners committed to bettering the lives of people impacted by kidney disease.

Industry Context

The approval of Vafseo addresses a significant unmet need in the treatment of anemia in dialysis patients, offering a new oral alternative to injectable erythropoiesis-stimulating agents, which are the current standard of care. This could potentially disrupt the market and provide a more convenient treatment option for patients.

Comparison to Industry Standards

• The current standard of care for anemia in dialysis patients primarily involves injectable erythropoiesis-stimulating agents (ESAs), such as darbepoetin alfa.
• Vafseo, as an oral HIF-PH inhibitor, offers a different mechanism of action by stimulating endogenous erythropoietin production, potentially providing a more physiological approach to managing anemia.
• The INNO2VATE program, which supported the approval of Vafseo, was compared to darbepoetin alfa, a common ESA, in clinical trials.
• While ESAs have been effective, they are associated with risks, including cardiovascular events, which are also a concern with Vafseo, as highlighted by the boxed warning.
• Other companies, such as FibroGen with Roxadustat, have also developed HIF-PH inhibitors, indicating a growing trend in this class of drugs for treating anemia in CKD patients.

Stakeholder Impact

• Shareholders will likely react positively to the FDA approval, potentially increasing the company's stock value.
• Patients on dialysis will have a new oral treatment option for anemia, potentially improving their quality of life.
• Healthcare providers will have a new tool for managing anemia in dialysis patients.
• Employees of Akebia will be involved in the commercialization of Vafseo.
• CSL Vifor will benefit from their partnership with Akebia in bringing Vafseo to the U.S. market.

Next Steps

• Akebia will commercialize Vafseo in the U.S.
• Akebia will execute a launch strategy to drive Vafseo toward the goal of becoming a new oral standard of care for adult dialysis patients.
• Akebia will host a conference call on March 28 to discuss the approval and launch plans.

Key Dates

Keywords

Vafseo, vadadustat, anemia, chronic kidney disease, dialysis, FDA approval, HIF-PH inhibitor, Akebia Therapeutics, erythropoietin